Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (101-110 of 361) with videos related to

Pageof 37
Sort By:
British Journal of Cancer|December 3, 2019
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M Wattenberg, Daniella Asch, Shun Yu, et al.
JCO Precision Oncology|February 1, 2022
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Parul Agarwal, Ronac Mamtani, et al.
Cancer|November 21, 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancerSusan M Domchek, Komal Jhaveri, Sujata Patil, et al.
Gynecologic Oncology|July 27, 2021
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomyMartha Hickey, Katrina M Moss, Efrosinia O Krejany, et al.
JCO Precision Oncology|February 24, 2022
<i>PTEN</i> Loss and <i>BRCA1</i> Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian CancerAdam A Kraya, Kara N Maxwell, Monika A Eiva, et al.
Cancer|October 15, 2008
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007Gordon F Schwartz, Kevin S Hughes, Henry T Lynch, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.
The Lancet. Oncology|July 10, 2022
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A Reiss, Rosemarie Mick, Ursina Teitelbaum, et al.
Frontiers in Cardiovascular Medicine|March 4, 2022
<i>BRCA1/2</i> Mutations and Cardiovascular Function in Breast Cancer SurvivorsBiniyam G Demissei, WenJian Lv, Nicholas S Wilcox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2010
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cellsRobert H Vonderheide, Patricia M LoRusso, Magi Khalil, et al.
Pageof 37

Showing results (101-110 of 361) with videos related to

Sort By:
Pageof 37
British Journal of Cancer|December 3, 2019
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M Wattenberg, Daniella Asch, Shun Yu, et al.
JCO Precision Oncology|February 1, 2022
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Parul Agarwal, Ronac Mamtani, et al.
Cancer|November 21, 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancerSusan M Domchek, Komal Jhaveri, Sujata Patil, et al.
Gynecologic Oncology|July 27, 2021
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomyMartha Hickey, Katrina M Moss, Efrosinia O Krejany, et al.
JCO Precision Oncology|February 24, 2022
<i>PTEN</i> Loss and <i>BRCA1</i> Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian CancerAdam A Kraya, Kara N Maxwell, Monika A Eiva, et al.
Cancer|October 15, 2008
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007Gordon F Schwartz, Kevin S Hughes, Henry T Lynch, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.
The Lancet. Oncology|July 10, 2022
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A Reiss, Rosemarie Mick, Ursina Teitelbaum, et al.
Frontiers in Cardiovascular Medicine|March 4, 2022
<i>BRCA1/2</i> Mutations and Cardiovascular Function in Breast Cancer SurvivorsBiniyam G Demissei, WenJian Lv, Nicholas S Wilcox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2010
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cellsRobert H Vonderheide, Patricia M LoRusso, Magi Khalil, et al.
Pageof 37